Clinical Trial Search

Primary: Percentage of Participants With Major Molecular Response (MMR) at Month 12 — 55.0 Percentage of participants — p=<0.0001

Primary: Percentage of Participants With Total Venous Thromboembolism — 19; 29; 17 Participants

Primary: Measurement of Skin Flora Recovery Post-prep Application Relative to Baseline — 0.91; 2.81; 0.59; 2.96 Log10 CFU/cm^2 — p=<0.0001

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) - Part A — 26.7; 100; 13.3 percentage of participants

Primary: Number of Participants With At Least One Treatment Emergent Adverse Event (TEAE) — 7; 6; 12; 12 Participants

Primary: Investigator Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) 2-level Responders — 6; 131; 8; 125 Participants

Primary: Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) Score — -1.6; -2.2; -2.5; -3.3 Score — p=0.0931

Primary: Event-free Survival — 1440; 1091 days — p=0.015

Primary: Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs) — 17 Participants

Primary: Overall Remission Rate (ORR) Per Independent Review Committee (IRC) (for ALL Participants) — 70.3 Percentage of participants — p=<0.0001

Primary: Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort

Primary: Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12 — 29.2; 66.7; 65.7; 72.5 percentage of participants — p=< 0.0001

Primary: Number of Metastatic Participants With Radiographic Response — 0 Participants

Primary: A Number of Participants With Non-serious and Serious Adverse Events 24 Hrs Post-transfusion — 0; 0; 0; 0 participants

Primary: Mean Kinetic Parameters Reflecting Fluorocholine (FCH) Fluorine 18 FCH (F-18) Influx (K1) — 0.562 K1 (min-1)